Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab175701-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $79.90 | |
| Ab175701-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $389.90 | |
| Ab175701-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,149.90 | |
| Ab175701-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,939.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Volociximab (anti-Integrin α5β1) - Primary antibody, specific to ITGA5; ITGB1, Human IgG4SP |
|---|---|
| Synonyms | M200 |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | ITGA5; ITGB1 |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | ANTAGONIST |
| Mechanism of action | Antibody of integrin α5β1;Antibody of integrin; alpha 5 subunit (fibronectin receptor; alpha polypeptide) |
| Product Description | Volociximab is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1. Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab (anti-Integrin α5β1)) has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs). |
| Isotype | Human IgG4SP |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 26.6 kDa (Light Chain) & 51.8 kDa (Heavy Chain), under reducing conditions; 190.8 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 558480-40-3 |
Volociximab (anti-Integrin α5β1) (Ab175701) - ELISA
Immobilized Human Integrin α5β1 Protein at 2.0 μg/mL can bind Volociximab (anti-Integrin α5β1) (Ab175701) with the EC
₅₀
of 9.58 ng/mL.
Volociximab (anti-Integrin α5β1) (Ab175701) - SEC
The purity of Volociximab (anti-Integrin α5β1) (Ab175701) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| IMGT/mAb-DB | 256 |
|---|
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0708319 | Certificate of Analysis | Jul 16, 2024 | Ab175701 |
| ZJ24F0708318 | Certificate of Analysis | Jul 16, 2024 | Ab175701 |
| ZJ24F0708317 | Certificate of Analysis | Jul 16, 2024 | Ab175701 |
| 1. Ramakrishnan V, Bhaskar V, Law DA, Wong MH, DuBridge RB, Breinberg D, O'Hara C, Powers DB, Liu G, Grove J et al.. (2006) Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent.. J Exp Ther Oncol, 5 (4): (273-86). [PMID:17024968] |
| 2. Bhaskar V, Zhang D, Fox M, Seto P, Wong MH, Wales PE, Powers D, Chao DT, Dubridge RB, Ramakrishnan V. (2007) A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo.. J Transl Med, 5 (3): (61). [PMID:18042290] |
| 3. Bhaskar V, Fox M, Breinberg D, Wong MH, Wales PE, Rhodes S, DuBridge RB, Ramakrishnan V. (2008) Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits.. Invest New Drugs, 26 (1): (7-12). [PMID:17786386] |
| 4. Ng CM, Bai S, Takimoto CH, Tang MT, Tolcher AW. (2010) Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients.. Cancer Chemother Pharmacol, 65 (2): (207-17). [PMID:19468731] |
| 5. Almokadem S, Belani CP. (2012) Volociximab in cancer.. Expert Opin Biol Ther, 12 (2): (251-7). [PMID:22192080] |
